FER

BARCELONA, Spain I January 16, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-Her3 immunotherapeutics in R&D: Her3-Targeted Immunotherapy Pipeline Review Target: Her3; human epidermal growth factor receptor 3; ErbB3 Product Category: Antibody; This product provides basic information on immunotherapeutics in R&D targeting Her3. This product consists of: This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day. HER3 is a member of the epidermal growth factor receptor (ERBB) family of tyrosine kinase receptors. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Her3 is overexpressed in a broad range of tumors and is associated with disease progression and poor survival. For example, more than 50% of melanoma, cervical, lung, gastric, colorectal, and ovarian cancers show overexpression of HER3, while in breast, pancreatic and prostate cancers the overexpression ranges between 25-40%. In addition, recent studies show that HER3 expression is significantly induced in tumors during metastasis (in colorectal) and during acquired resistance to tyrosine kinase inhibitors (TKI) in lung cancers. This widespread overexpression of HER3 makes it an ideal target for antibody drug conjugates (ADCs) and bispecific antibodies targeting Her3 and a second, co-expressed tumor associated antigen. In addition, these new drug modalities promise improved antitumor activity compared to first generation naked antibodies. The report “ Her3-Targeted Immunotherapy Pipeline Review ” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/her3-targeted-immunotherapy-pipeline-review/ About La Merie Publishing La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers. La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest. SOURCE: La Merie Publishing

本文为转化医学网原创，转载请注明出处 作者：Rainbow 导读： 胶质瘤是一种侵袭性的脑肿瘤，占据中枢神经系统恶性肿瘤的80％。 12月4日，中国医科大学附属盛京医院刘静团队在期刊《Cell Death & Disease》上在线发表题为“HECW1 induces NCOA4-regulated ferroptosis in glioma through the ubiquitination and degradation of ZNF350”的研究论文， 本研究首次揭示了HECW1和ZNF350对胶质瘤的影响及它们在评估患者预后方面的潜在价值。研究人员探索并证明了HECW1/ZNF350/NCOA4通路在调节铁死亡中的作用和机制，并确定了胶质瘤治疗的新分子靶点。 https://www.nature.com/articles/s41419-023-06322-w 研究背景 01 胶质瘤的特点是其高度侵袭性和高死亡率。尽管手术干预和化放疗取得了重大进展，但胶质瘤患者的中位生存时间仍然很短，需要新的治疗策略来治疗胶质瘤。 铁死亡（ferroptosis）作为一种新型细胞死亡方式，已成为越来越受关注的研究课题。与其他细胞死亡机制不同，铁积累和活性氧（ROS）的产生，以及线粒体嵴的减少或消失是铁死亡的独特特征。核受体共激活因子4（NCOA4）与重链1的铁蛋白结合，并将其运输到溶酶体进行降解，从而能够在细胞中诱导铁死亡。越来越多的证据表明，铁死亡对肿瘤的生物过程具有复杂的调控作用。 泛素化（ubiquitination）是指真核生物中广泛存在的蛋白质后转录修饰，调控了许多生物过程。ATP、泛素活化酶(E1)、泛素连接酶(E2)和泛素连接酶(E3)对于蛋白质的泛素化和降解是不可或缺的。E3决定了泛素-底物结合的特异性，使其成为泛素化调控研究中的热门课题。含有HECT、C2和WW结构域的E3泛素蛋白连接酶1（HECW1）属于HECT家族，在脑肿瘤中首次被发现。 锌指蛋白350（ZNF350）是在对BRCA1（乳腺癌类型1易感蛋白）相关蛋白进行酵母双杂交分析时鉴定出的一个典型的含有KRAB结构域的锌指蛋白。ZNF350被确认为一个转录抑制因子，可以与其他蛋白形成复合物，或者以单因子形式发挥直接的转录抑制作用。因此，ZNF350在各种肿瘤的发展中起着重要作用。然而，ZNF350在胶质瘤中的潜在影响和机制尚未明确。 研究发现 02 在这项研究中，研究人员发现HECW1可以阻断胶质瘤细胞的进展，并增强铁积累和脂质过氧化（LPO），这是通过诱导NCOA4介导的铁死亡来实现的。通过筛选和验证，研究人员确认了ZNF350在HECW1对NCOA4的正调控中的介导作用。HECW1诱导的泛素化干扰了ZNF350的蛋白稳定性。ZNF350通过直接结合转录起始位点来抑制NCOA4的转录活性。在研究中，研究人员展示了HECW1/ZNF350/NCOA4通路在胶质瘤中对铁死亡的调控机制，这可能为胶质瘤治疗提供了一种新的策略。 HECW1通过诱导胶质瘤 细胞 铁 死亡发挥肿瘤抑制功能 03 为了揭示HECW1在癌症抑制中发挥作用的机制，研究人员使用不同的细胞死亡抑制剂处理了胶质瘤细胞。首先，研究人员通过Western Blot分析确定oeHECW1转染的细胞中HECW1的蛋白水平。HECW1的过表达显著降低了胶质瘤细胞的生长。这种效应被铁死亡抑制剂（Fer-1）所逆转。此外，HECW1的过表达明显增加了胶质瘤细胞的死亡，而这种效应在很大程度上被Fer-1处理所逆转。 在进一步的实验中，研究人员验证了HECW1的过表达显著提高了MDA、细胞内ROS（H2O2）和铁离子水平。接下来，研究人员揭示了HECW1沉默对铁死亡的影响。铁死亡诱导剂（erastin、RSL3）显著抑制了胶质瘤细胞的生长并加速了细胞死亡。然而，这种效应在HECW1沉默后很大程度上被抵消。三个铁死亡诱导剂也在HECW1沉默后显著降低。 结果表明，HECW1在胶质瘤细胞中引起铁积累、LPO和铁死亡。 研究结果 04 综上所述， 本研究首次揭示了HECW1和ZNF350对胶质瘤的影响及它们在评估患者预后方面的潜在价值。研究人员探索并证明了HECW1/ZNF350/NCOA4通路在调节铁死亡中的作用和机制，并确定了胶质瘤治疗的新分子靶点。 参考资料： https://www.nature.com/articles/s41419-023-06322-w 注：本文旨在介绍医学研究进展，不能作为治疗方案参考。如需获得健康指导，请至正规医院就诊。 热门·直播/活动 🕓 北京｜12月19日-20日 ▶第四届单细胞测序技术应用研讨会暨单细胞&空间组学研讨会（日程稍后公布） 点击对应文字 查看详情

NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO). Ms. DiCicco has more than 25 years of experience in the life sciences industry, currently serving as an independent financial and board advisor to companies, often in the role of interim CFO. “Wendy’s broad and deep experience in both strategic and operational aspects of finance will be invaluable assets to our management team as we work to bring nomacopan through its key milestones, create value for our investors, and make a meaningful difference for patients who have significant unmet needs,” said Rachelle Jacques, President and CEO of Akari. Ms. DiCicco served as CFO for Renovacor, a pre-clinical biopharmaceutical company developing a gene therapy for cardiovascular disease. Initially as interim CFO, transitioning to permanent, she led the company through Initial Public Offering (IPO) in 2021 and sale to Rocket Pharmaceuticals in December 2022. She also served as interim CFO for FerGene, Inc. a Phase 3 urologic oncology gene therapy company from January 2020 through May 2022. Previously, she was CFO and Chief Operating Officer (COO) of Centinel Spine and the President and COO of Camber Spine, both developers of best-in-class spinal implants. She has held CFO roles for several pre-IPO, private equity backed medical device and biotech companies, in varying stages of commercialization. Her first CFO role was with Kensey Nash Corporation, a publicly traded developer and manufacturer of biologics and medical devices in the cardiovascular and orthopedics industries, where she advanced the company from a pre-revenue IPO stage to approximately $100 million in global revenue across multiple product platforms. Her career started in public accounting at Deloitte & Touche. Ms. DiCicco currently serves on the public company Board of Directors of EyePoint Pharmaceuticals, Inc. where she serves as the Audit Committee Chair. In addition, she serves on the boards of Imvax, Inc. and ExpressCells. Ms. DiCicco has also served on the boards of SWK Holdings Corp, II-VI, Inc. (now Coherent Corp), Sincerus Pharmaceuticals, Carmell Therapeutics, SynCardia Systems and CannaPharma Rx. She is currently on the Board of Directors of the Philadelphia Chapter of the National Association of Corporate Directors. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed Certified Public Accountant (CPA). She also is an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD). About Akari Therapeutics Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com. Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. For more information Investor Contact:Mike MoyerLifeSci Advisors(617) 308-4306mmoyer@lifesciadvisors.com Media Contact:Eliza SchleifsteinSchleifstein PR (917) 763-8106eliza@schleifsteinpr.com